In the spring of 2019, The Food and Drug Administration granted approval for two breakthrough medicines that act rapidly to alleviate symptoms of major depression. Esketamine, a drug administered via…
Read More
Researchers led by 2013 BBRF Young Investigator Conor Liston, M.D., Ph.D., have just reported a surprising finding about the drug ketamine, concerning the way it acts on the brain.
Approved many…
Read More
On February 12th, an FDA advisory panel recommended overwhelmingly that the agency approve a drug called esketamine for the rapid relief of depression in patients who have not been helped by existing…
Read More
Although many studies in recent years have provided evidence that ketamine, an anesthetic drug, can provide rapid relief to people with deep depression, this research has not shed much light on what…
Read More
Alan F. Schatzberg, M.D.
Stanford University School of Medicine
Scientific Council Member (Joined 2005)
2005 Falcone Prizewinner for Outstanding Achievement in
Affective Disorders Research (Colvin…
Read More
